Eva‐Maria Wagner‐Drouet

Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents—a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group

Esther Schuler, Eva‐Maria Wagner‐Drouet, Salem Ajib et al. · Annals of Hematology · 2020 · 65 citations · Full text

Treosulfan compared with <scp>reduced‐intensity</scp> busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial

Dietrich W. Beelen, Matthias Stelljes, Péter Reményi et al. · American Journal of Hematology · 2022 · 56 citations · Full text

Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial

Matthias Stelljes, Jan Moritz Middeke, Gesine Bug et al. · The Lancet Haematology · 2024 · 44 citations · Full text

A multicenter prospective, randomized, placebo-controlled phase II/III trial for preemptive acute graft-versus-host disease therapy

Eva M. Weissinger, Jochen Metzger, Michael Schleuning et al. · Leukemia · 2020 · 17 citations · Full text

Thiotepa–fludarabine–treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trial

Jürgen Finke, Claudia Schmoor, Matthias Stelljes et al. · Bone Marrow Transplantation · 2022 · 10 citations · Full text